Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Neuroimmunology|July 20, 2024
Infection, vaccination and narcolepsy type 1: Evidence and potential molecular mechanismsIkram Ayoub, Sean A Freeman, Abdelhadi Saoudi, et al.
Seminars in Immunology|May 15, 2025
Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approachesSean A Freeman, Ikram Ayoub, Yves Dauvilliers, et al.
Cellular and Molecular Life Sciences : CMLS|October 31, 2015
Mechanisms of sodium channel clustering and its influence on axonal impulse conductionSean A Freeman, Anne Desmazières, Desdemona Fricker, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 21, 2026
No association between the wearing-off effect and α4-integrin receptor saturation in natalizumab treated patients with relapsing-remitting multiple sclerosisSean A Freeman, Celso Rual, Damien Biotti, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 26, 2023
Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody TherapySean A Freeman, Bruno Lemarchant, Tifanie Alberto, et al.
Glia|March 3, 2020
An alternative mechanism of early nodal clustering and myelination onset in GABAergic neurons of the central nervous systemMelina Thetiot, Sean A Freeman, Thomas Roux, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2025
Prevalence of hypogammaglobulinemia after non-anti-CD20 therapies and impact of switching to rituximab/ocrelizumab in multiple sclerosisMarine Perriguey, Camille Rigollet, Sean A Freeman, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 7, 2015
Acceleration of conduction velocity linked to clustering of nodal components precedes myelinationSean A Freeman, Anne Desmazières, Jean Simonnet, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 20, 2025
Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosisCamille Rigollet, Sean A Freeman, Marine Perriguey, et al.
Pageof 1